Maxion Therapeutics Secures £58m in Series A Funding
Deal News | Mar 17, 2025 | UK Tech Funding
Maxion Therapeutics, a biotech firm based in Cambridge, has successfully secured £58 million in a Series A funding round. This financing marks one of the largest European biotech private financings since early 2024 and was led by General Catalyst, with participation from British Patient Capital, Solasta Ventures, and Eli Lilly and Company. Maxion specializes in developing antibody-based drugs, known as KnotBodies, aimed at addressing issues associated with targeting ion channels and GPCRs. These drugs are designed to treat a spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease, with additional early-stage applications for pain and cardiovascular conditions. CEO Arndt Schottelius emphasized the fundraising highlights Maxion’s potential as a key player in biologic drug development, with the hope of offering transformative therapeutic options for unmet medical needs.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare Investment
Geography
- United Kingdom – Maxion Therapeutics is based in Cambridge, UK, and British Patient Capital is one of the investors.
- European Union – The article references one of the largest European biotech financings, suggesting a broader EU relevance.
Industry
- Biotechnology – The development of drugs and treatments through biological processes, as exemplified by Maxion Therapeutics' work on KnotBodies to target inflammatory diseases.
- Pharmaceuticals – Relates to the development and commercialization of drug therapies, such as Maxion Therapeutics' programs targeting various diseases.
- Healthcare Investment – Involves funding rounds and investments in healthcare technologies and therapies, like the Series A round for Maxion Therapeutics.
Financials
- £58 million – The total raised in the Series A funding round by Maxion Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Maxion Therapeutics | Target | Company | A Cambridge-based biotech firm focusing on developing KnotBodies for treating inflammatory diseases. |
| General Catalyst | Lead Investor | Company | A venture capital firm leading the Series A investment round for Maxion Therapeutics. |
| British Patient Capital | Investor | Company | A corporation investing in the Series A of Maxion Therapeutics, focusing on life sciences. |
| Solasta Ventures | Investor | Company | An investment firm participating in the Series A funding of Maxion Therapeutics. |
| Eli Lilly and Company | Investor | Company | A global pharmaceutical company participating as an investor in Maxion Therapeutics' funding round. |
| Arndt Schottelius | CEO | Person | CEO of Maxion Therapeutics, highlighting the significance of the fundraising and potential of KnotBodies. |
| Emma Johnson | Senior Investment Manager | Person | Senior investment manager at British Patient Capital, commenting on Maxion's contributions to antibody therapeutics. |